# The INFECIR-2 Albumin Prevention Study

> **NCT02034279** · PHASE4 · TERMINATED · sponsor: **EASL - CLIF Consortium** · enrollment: 136 (actual)

## Conditions studied

- Advanced Chronic Liver Disease
- Urinary Infection
- Pneumonia
- Cholangitis
- Other Bacterial Diseases

## Interventions

- **DRUG:** Albumin

## Key facts

- **NCT ID:** NCT02034279
- **Lead sponsor:** EASL - CLIF Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05
- **Primary completion:** 2016-12-31
- **Final completion:** 2017-02-10
- **Target enrollment:** 136 (ACTUAL)
- **Why stopped:** Low recruitment rate and expiration of the study drug
- **Last updated:** 2017-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02034279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02034279, "The INFECIR-2 Albumin Prevention Study". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT02034279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*